STOCK TITAN

Aspira Women's Health Inc. - AWH STOCK NEWS

Welcome to our dedicated page for Aspira Women's Health news (Ticker: AWH), a resource for investors and traders seeking the latest updates and insights on Aspira Women's Health stock.

Aspira Women's Health Inc. (Nasdaq: AWH) is a pioneering company focused on the development and commercialization of noninvasive diagnostic tests for gynecologic diseases. The company is at the forefront of women's health, offering innovative solutions that leverage bio-analytical techniques and artificial intelligence.

One of Aspira's flagship products is OvaSuite, a comprehensive portfolio of blood tests designed to assess the risk of ovarian cancer. This suite includes the well-known OvaWatch and Ova1Plus tests. OvaWatch, with a negative predictive value of 99%, is instrumental in evaluating ovarian cancer risk in women with adnexal masses that appear indeterminate or benign, potentially allowing them to avoid unnecessary surgeries. Ova1Plus combines two FDA-cleared tests, Ova1® and Overa®, providing a robust assessment for women scheduled for surgery due to pelvic masses.

In addition to ovarian cancer diagnostics, Aspira is expanding its test pipeline to address other pressing women's health issues. The company is developing EndoCheck, the first-ever noninvasive test for identifying endometriomas, a common form of endometriosis. Another promising test in development is OvaMDx, which combines microRNA and protein biomarkers with patient data to enhance the accuracy of ovarian cancer risk assessments.

The company's commitment to innovation is reflected in its recent achievements. Aspira has published significant clinical studies demonstrating the efficacy of OvaWatch in longitudinal monitoring of ovarian cancer risk, which could significantly reduce surgical backlogs and unnecessary referrals. Furthermore, Aspira has made strides in market access, securing payer coverage from Anthem Blue Cross and expanding its reach to millions of lives across various health plans.

Financially, Aspira has shown remarkable progress. In 2023, the company significantly reduced its operational cash use while increasing revenues and test volumes. These accomplishments were accompanied by important enhancements to their commercial organization and the achievement of key market access milestones. As of December 31, 2023, Aspira had $2.9 million in cash and raised an additional $5.5 million through a registered direct offering and private placement.

The management team, led by CEO Nicole Sandford, has positioned Aspira for substantial growth in 2024 and beyond. The company's forward-looking strategies and robust test pipeline are set to meet the growing demand for noninvasive diagnostics in women's health, offering new hope and improved outcomes for millions of women worldwide.

Rhea-AI Summary

Aspira Women’s Health (Nasdaq: AWH) has signed an agreement with Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University Lodz to develop a high-risk early detection test for ovarian cancer using novel microRNA technology. This collaboration aims to enhance early detection, which significantly increases survival rates, as ovarian cancer has a high mortality rate. The initiative reflects Aspira's commitment to women's health and creating innovative testing options, particularly in assessing ovarian cancer risk.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
none
-
Rhea-AI Summary

Aspira Women’s Health, Inc. (Nasdaq: AWH) will announce its financial results for Q4 and full year 2020 on March 25, 2021, after market close. An investor conference call and webcast is scheduled for 4:30 p.m. ET on the same day. The company focuses on innovative testing options in women’s health, particularly in ovarian cancer risk assessment and pelvic diseases. Its FDA-cleared products OVA1® and OVERA® assist in evaluating ovarian malignancy risk. Aspira is committed to improving gynecologic health outcomes and addressing ethnic disparities in healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
conferences earnings
-
Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) announced its subsidiary, Aspira Labs, has achieved credentialing with New York State’s Medicaid program, covering an estimated 6.5 million lives starting April 1, 2021. This credentialing expands the total covered lives for Aspira's OVA1® test to 179 million nationwide, enhancing access for ovarian cancer risk assessment. Aspira Labs is now credentialed in the top 9 U.S. states by Medicaid population, totaling nearly 60 million lives. The company aims to address health disparities in ovarian cancer risk detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.66%
Tags
none
Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) announced the appointment of Ms. Nicole Sandford to its Board of Directors. With extensive experience in regulatory leadership and corporate governance, Sandford is expected to play a crucial role in the company's growth. She previously served at Deloitte and is passionate about improving women’s health, particularly in ovarian cancer. Sandford aims to leverage her skills to aid Aspira in achieving its mission. Aspira focuses on innovative testing solutions for gynecologic health and is known for its FDA-cleared products, OVA1 and OVERA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
management
-
Rhea-AI Summary

Aspira Women's Health Inc. (Nasdaq: AWH) emphasizes its commitment to mitigating racial disparities in ovarian cancer risk assessment during Black History Month. The company aims to enhance testing access for women of all backgrounds, particularly those at high risk. Notably, Black women face significantly lower 5-year survival rates—36% compared to 46% for White women. Aspira's product OVA1plus is designed to improve risk detection in Black women through its advanced multi-biomarker algorithm. CEO Valerie Palmieri highlights the urgent need for equitable healthcare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
none
-
Rhea-AI Summary

Aspira Women's Health, Inc. (Nasdaq: AWH) announced its participation in the 2021 BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference happening from February 17-19. The company will present on February 18 at 9:30 am Eastern Time. Aspira focuses on innovative testing solutions for women's health, particularly in ovarian cancer risk assessment. Their product portfolio includes FDA-cleared tests like OVA1® and OVERA®, and they aim to address ethnic disparities in health outcomes. For more details, visit www.aspirawh.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
conferences
Rhea-AI Summary

Aspira Women’s Health (Nasdaq: AWH) announced the integration of National Comprehensive Cancer Network® (NCCN®) management recommendations into its Aspira GenetiX Clinical reports. This personalized hereditary cancer genetic risk testing service focuses on gynecologic cancers such as endometrial, ovarian, and cervical cancers. The inclusion of NCCN guidelines strengthens the product's position in the market and enhances support for healthcare providers managing high-risk patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
-
Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) announced a public offering of 6,000,000 shares at $7.50 per share, with a potential increase of 900,000 shares via underwriter option. The offering, managed by William Blair & Company and Truist Securities, aims to raise approximately $45 million, potentially $51.75 million if the option is fully exercised. Funds will support sales, marketing, working capital, and R&D. The offering is set to close on February 8, 2021. The shares are offered under an effective shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.83%
Tags
-
Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) has initiated an underwritten public offering of its common stock, with market conditions influencing its completion. The offering will include a 30-day underwriter option for an additional 15% of shares. Proceeds are intended for sales and marketing, working capital, strategic hires, product expansion, and potential acquisitions. The offering is backed by a previously filed shelf registration statement with the SEC, though no specific commitments for acquisitions are currently in place.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.83%
Tags
Rhea-AI Summary

Aspira Women’s Health Inc. (Nasdaq: AWH) has announced its expansion as a participating laboratory network provider for Highmark’s commercial health insurance products in Pennsylvania and West Virginia. This initiative will enhance access to OVA1® and OVERA® tests, which assess ovarian malignancy risks in women with adnexal masses. Aspira now provides network access to over 154 million individuals, crucial for improving healthcare access for women, according to CEO Valerie Palmieri. The company aims to close ethnic disparities in ovarian cancer risk assessment and advance gynecologic health outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.12%
Tags
none

FAQ

What is the current stock price of Aspira Women's Health (AWH)?

The current stock price of Aspira Women's Health (AWH) is $0.77 as of December 20, 2024.

What is the market cap of Aspira Women's Health (AWH)?

The market cap of Aspira Women's Health (AWH) is approximately 12.5M.

What is Aspira Women's Health Inc. known for?

Aspira Women's Health Inc. is known for developing and commercializing noninvasive diagnostic tests for gynecologic diseases, particularly ovarian cancer.

What products does Aspira offer?

Aspira offers OvaSuite, which includes OvaWatch and Ova1Plus. These are blood tests designed to assess the risk of ovarian cancer in women with adnexal masses.

How effective is OvaWatch?

OvaWatch has a negative predictive value of 99%, making it highly effective in assessing ovarian cancer risk in women with indeterminate or benign adnexal masses.

What is Ova1Plus?

Ova1Plus is a combination of two FDA-cleared tests, Ova1® and Overa®, designed to assess the risk of ovarian malignancy in women planned for surgery.

What recent achievements has Aspira made?

Aspira has recently published significant clinical studies, secured Anthem Blue Cross payer coverage, and reduced operational cash use while increasing revenues and test volumes.

What is EndoCheck?

EndoCheck is the first-ever noninvasive test developed by Aspira to identify endometriomas, a common form of endometriosis.

How has Aspira performed financially recently?

In 2023, Aspira reduced its operational cash use, increased revenues, and achieved key market access milestones. They also raised $5.5 million through a direct offering and private placement.

Who leads Aspira Women's Health Inc.?

Aspira is led by CEO Nicole Sandford, who has guided the company through significant growth and innovation in women's health diagnostics.

What is OvaMDx?

OvaMDx is an in-development test that combines microRNA and protein biomarkers with patient data to enhance the sensitivity and specificity of ovarian cancer risk assessments.

How does Aspira's test pipeline address women's health issues?

Aspira's test pipeline, including EndoCheck and OvaMDx, aims to provide noninvasive diagnostic solutions for ovarian cancer and endometriosis, improving care and outcomes for millions of women.

Aspira Women's Health Inc.

Nasdaq:AWH

AWH Rankings

AWH Stock Data

12.50M
11.68M
30.94%
13.89%
3.35%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
AUSTIN